HYPHENS PHARMA INTERNATIONAL LIMITED
Hyphens Pharma International Limited is a public company limited by shares incorporated in Singapore on 12 December 2017 (UEN 201735688C) and listed on the Catalist board of the Singapore Exchange (SGX: 1J5; ISIN SG1EE4000006) since 18 May 2018. The company is the listed holding entity for the Hyphens Pharma group, a specialty pharmaceutical and consumer healthcare business whose principal Singapore operating subsidiary, Hyphens Pharma Pte. Ltd., traces its commercial origins to 1988.
Hyphens Pharma International Limited operates through three core segments: Pharmaceuticals & Medical Aesthetics, in which it markets and distributes specialty pharmaceutical, medical aesthetics and hospital-use products under license from principals across dermatology and other specialties; Proprietary Brands, comprising its own dermatological, health-supplement and consumer-healthcare brands sold through its Novem and Ocean Health entities; and Digital Platform & E-Pharmacy, centred on its DocMed Technology e-pharmacy and telehealth platform.
The group’s direct operating presence spans Singapore, Malaysia, Vietnam, Indonesia and the Philippines, with distribution reach extending into Thailand, Cambodia, Brunei, Bangladesh, Myanmar, Hong Kong SAR and Oman. For the financial year ended 31 December 2024, the group reported consolidated revenue of S$195.4 million, up 14.6% from S$170.6 million in FY2023, with net profit rising 26.5% year-on-year. In July 2024 the group increased its stake in DocMed Technology Pte. Ltd. from 89.76% to 90.00%. Registration with the Accounting and Corporate Regulatory Authority (ACRA) remains active; active registry status does not by itself indicate that the company is currently trading.
- Company fundamentals
- Corporate linkage & group structures
- Digitized company financials
- Firmographics — websites, social profiles, revenue and employee estimates
Shareholders
Shareholders of Hyphens Pharma International Limited
Hyphens Pharma International Limited is a Catalist-listed company, and its shareholder base combines founder/director holdings with free-float public and institutional investors. The company’s own corporate disclosures identify Mr Lim See Wah, Executive Chairman and Chief Executive Officer, as founder and a substantial shareholder, together with Dr Tan Kia King, Non-Executive Director, who also holds a substantial interest. Contemporaneous reporting on the company’s May 2018 Catalist offer document described the pre-listing holding vehicle, Innomed Holdings Pte. Ltd., as holding approximately 65.4% of the company at that time, of which Mr Lim See Wah held approximately 61.1%, with the balance held by Mr Tan Chwee Koon. Third-party data aggregators report varying current individual percentages for Mr Lim See Wah (from roughly 38.8% to 48.09%) and for Dr Tan Kia King (in the high-20% range); these figures could not be independently corroborated from a primary SGX substantial-shareholder notice or the FY2025 annual report’s statistics-of-shareholdings section within the sources reviewed, so no single current percentage is reported here as verified.
Data availability
Singapore-listed companies disclose substantial shareholders (holdings of 5% or more) under the Securities and Futures Act, but this review did not locate a directly accessible primary filing setting out exact current percentages. Availability is classified as Major shareholders only / Partial, based on company announcements naming Mr Lim See Wah and Dr Tan Kia King as founder-director shareholders, pending confirmation from the FY2025 annual report’s statistics-of-shareholdings section or a Form of Notification of Interest filed on SGXNet. Information date: 2026-09-11 (retrieval date).
Sources
SGX corporate information page for Hyphens Pharma International Limited, links.sgx.com/1.0.0/corporate-information/2843, retrieved 2026-09-11; Hyphens Pharma International Limited Board of Directors page, hyphensgroup.com/about-us/board-of-directors/, retrieved 2026-09-11; contemporaneous 2018 reporting on the Catalist offer document’s pre-listing shareholding structure, retrieved 2026-09-11.
Officers
13
Directors and officers of Hyphens Pharma International Limited
The board of Hyphens Pharma International Limited comprises six current directors, per the company’s own investor-relations disclosures. Mr Lim See Wah serves as Chairman, Executive Director and Chief Executive Officer, and Dr Tan Kia King as Non-Executive Director; both were appointed in December 2017 at incorporation. Three independent directors were appointed later: Mr Heng Wee Koon (Lead Independent Director, appointed April 2018), Mr Ng Eng Leng (Independent Director, appointed April 2018), Ms Tan Seok Hoong, also known as Mrs Audrey Liow (Independent Director, appointed July 2019), and Mr Chan Kiat (Independent Director, appointed November 2020). Ms Lim Sher Mei serves as Company Secretary, per the SGX corporate information page. The on-file registry extract also lists several senior operating personnel across group subsidiaries (including a managing director role spanning two operating units, a Head of Regulatory Affairs, a Head of HR & Administration and a Chief Technology Officer); these appear to be operational appointments at subsidiary or group level rather than statutory directors of the listed entity, and the source does not clearly distinguish them from board-level officers. Nationality is not officially disclosed for any of these individuals in the sources reviewed and is not inferred here from name, residence or correspondence address; the on-file address records show Singapore as a correspondence-country field only, not a residence or nationality.
Data availability
Singapore’s ACRA registry publishes officer appointment records, but exact appointment or resignation dates for the operational (non-board) personnel, and any nationality data, were not available in the sources reviewed; availability is classified as Partial. Board appointment dates are drawn from the company’s official Board of Directors webpage rather than a dated ACRA extract, so they should be treated as approximate to the month stated. Information date: 2026-09-11 (retrieval date).
Sources
Hyphens Pharma International Limited Board of Directors page, hyphensgroup.com/about-us/board-of-directors/, retrieved 2026-09-11; SGX corporate information page, links.sgx.com/1.0.0/corporate-information/2843, retrieved 2026-09-11 (Company Secretary).
Registry feed — rows exactly as filed with Accounting and Corporate Regulatory Authority (ACRA), including entries the profile above does not cover.
Group Structure
Group structure of Hyphens Pharma International Limited
Hyphens Pharma International Limited is the ultimate listed parent of the Hyphens Pharma group, an SGX Catalist-listed specialty pharmaceutical and consumer-healthcare group. Its principal Singapore operating subsidiary is Hyphens Pharma Pte. Ltd. (UEN 198600174G), which in turn holds a group of Singapore, Malaysian and Philippine entities spanning branded-products, proprietary-pharma and medical-aesthetics distribution. The company’s own FY2024 results disclosures additionally confirm that DocMed Technology Pte. Ltd., its digital-health and e-pharmacy platform subsidiary, was 90.00% owned by the group as at 15 July 2024, following a 2022 minority investment by Metro Holdings Limited; this entity is not reflected in the on-file corporate-linkage data and is added here as a verified, sourced correction. Ownership percentages for the other listed subsidiaries were not disclosed in the sources reviewed. Information is current as of the FY2024 results announcement (on or about February 2025) and the FY2025 annual-report filing (10 April 2026).
Verified corporate relationships
| Entity | Country | Registration number | Relationship | Ownership | Status | Information date |
|---|---|---|---|---|---|---|
| Hyphens Pharma Pte. Ltd. | Singapore | 198600174G | Direct subsidiary | Ownership percentage not disclosed | Active | 2026-08-11 |
| Novem Healthcare Pte Ltd | Singapore | 199204449D | Indirect subsidiary | Ownership percentage not disclosed | Active | 2026-08-11 |
| Novem Pharma Private Limited | Singapore | 201000707C | Indirect subsidiary | Ownership percentage not disclosed | Active | 2026-08-11 |
| Ardence Aesthetics Pte. Ltd. | Singapore | 201709423M | Indirect subsidiary | Ownership percentage not disclosed | Active | 2026-08-11 |
| Hyphens Pharma Sdn. Bhd. | Malaysia | 200401002541 | Indirect subsidiary | Ownership percentage not disclosed | Active | 2026-08-11 |
| Ocean Health Pte. Ltd. | Singapore | 199402610K | Indirect subsidiary | Ownership percentage not disclosed | Active | 2026-08-11 |
| Hyphens Pharma Philippines, Inc. | Philippines | 006-897-017-000 | Indirect subsidiary | Ownership percentage not disclosed | Active | 2026-08-11 |
| DocMed Technology Pte. Ltd. | Singapore | Not disclosed in sources reviewed | Direct subsidiary | 90.00% (as at 15 July 2024) | Active | 2024-07-15 |
Recent structural changes
On 15 July 2024, the group acquired a further 0.24% interest in DocMed Technology Pte. Ltd., raising its stake from 89.76% to 90.00%, following a 2022 minority investment by Metro Holdings Limited that first reduced Hyphens Pharma’s stake in DocMed below 100%.
Data availability
Corporate-linkage information for this group is classified as Partial: the immediate operating subsidiary and several second-tier entities are identified with registration numbers, but ownership percentages for most subsidiaries other than DocMed Technology Pte. Ltd. were not disclosed in the sources reviewed, and the on-file registry data omitted at least one verified subsidiary (DocMed Technology Pte. Ltd.), which is corrected here.
Sources
Hyphens Pharma International Limited FY2024 results media release and related coverage referencing the filing, retrieved 2026-09-11; Hyphens Pharma International Limited corporate profile, hyphensgroup.com/about-us/corporate-profile/, retrieved 2026-09-11; Zavia.ai on-file corporate-linkage data (last synced 2026-08-11).
HYPHENS PHARMA INTERNATIONAL LIMITED
Singapore
Get complete shareholder and officer records, ultimate beneficial owner resolution, and ongoing ownership monitoring.
Frequently Asked Questions
What is Hyphens Pharma International Limited's registration number?
Its Singapore UEN is 201735688C, filed with the Accounting and Corporate Regulatory Authority (ACRA).
When was Hyphens Pharma International Limited incorporated?
It was incorporated in Singapore on 12 December 2017, as confirmed by the SGX corporate information page. This corrects an on-file incorporation date of 2 November 2016, which predates the company's 2017-prefixed UEN and was internally inconsistent with it.
Is Hyphens Pharma International Limited listed on a stock exchange?
Yes. It has traded on the Catalist board of the Singapore Exchange under the ticker 1J5 (ISIN SG1EE4000006) since 18 May 2018.
What does Hyphens Pharma International Limited do?
It is the listed holding company of a specialty pharmaceutical and consumer healthcare group operating through Pharmaceuticals & Medical Aesthetics, Proprietary Brands, and Digital Platform & E-Pharmacy segments.
Where does the Hyphens Pharma group operate?
It has direct operations in Singapore, Malaysia, Vietnam, Indonesia and the Philippines, with distribution reach into Thailand, Cambodia, Brunei, Bangladesh, Myanmar, Hong Kong SAR and Oman.
Who is the founder and CEO of Hyphens Pharma International Limited?
Mr Lim See Wah is the founder, and serves as Chairman, Executive Director and Chief Executive Officer; he was appointed a director in December 2017 at incorporation.
Who are the other directors of Hyphens Pharma International Limited?
The board also includes Dr Tan Kia King (Non-Executive Director), Mr Heng Wee Koon (Lead Independent Director), Mr Ng Eng Leng (Independent Director), Ms Tan Seok Hoong, also known as Mrs Audrey Liow (Independent Director), and Mr Chan Kiat (Independent Director).
Who is the company secretary of Hyphens Pharma International Limited?
Ms Lim Sher Mei serves as Company Secretary, per SGX's corporate information page.
What was Hyphens Pharma's revenue in FY2024?
The group reported consolidated revenue of S$195.4 million for the year ended 31 December 2024, up 14.6% from S$170.6 million in FY2023, with net profit up 26.5% year-on-year.
What is Hyphens Pharma Pte. Ltd.'s relationship to Hyphens Pharma International Limited?
Hyphens Pharma Pte. Ltd. (UEN 198600174G) is the group's principal Singapore operating subsidiary and a direct subsidiary of the listed parent, Hyphens Pharma International Limited.
Does Hyphens Pharma International Limited wholly own its subsidiaries?
Not entirely; for example, it held a 90.00% stake in DocMed Technology Pte. Ltd. as at 15 July 2024, following a minority investment by Metro Holdings Limited in 2022.
Who are the substantial shareholders of Hyphens Pharma International Limited?
Founder-director Mr Lim See Wah and Dr Tan Kia King are identified in company disclosures as substantial shareholders; precise current percentage holdings vary across third-party sources and could not be confirmed from a primary SGX filing at the time of this review.
What industries does Hyphens Pharma International Limited serve?
It serves the pharmaceutical distribution, medical aesthetics, dermatology, consumer healthcare and digital health/telehealth markets across Southeast Asia.
What is Hyphens Pharma International Limited's registered country?
Singapore, where it is registered with the Accounting and Corporate Regulatory Authority (ACRA) under UEN 201735688C with active status.